JPS629092B2 - - Google Patents
Info
- Publication number
- JPS629092B2 JPS629092B2 JP52148343A JP14834377A JPS629092B2 JP S629092 B2 JPS629092 B2 JP S629092B2 JP 52148343 A JP52148343 A JP 52148343A JP 14834377 A JP14834377 A JP 14834377A JP S629092 B2 JPS629092 B2 JP S629092B2
- Authority
- JP
- Japan
- Prior art keywords
- urokinase
- gelatin
- aqueous solution
- molecular weight
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 65
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 65
- 229960005356 urokinase Drugs 0.000 claims description 65
- 108010010803 Gelatin Proteins 0.000 claims description 32
- 239000008273 gelatin Substances 0.000 claims description 32
- 229920000159 gelatin Polymers 0.000 claims description 32
- 235000019322 gelatine Nutrition 0.000 claims description 32
- 235000011852 gelatine desserts Nutrition 0.000 claims description 32
- 239000007864 aqueous solution Substances 0.000 claims description 27
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 239000004471 Glycine Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 238000011146 sterile filtration Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 6
- 230000000087 stabilizing effect Effects 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- DPEYHNFHDIXMNV-UHFFFAOYSA-N (9-amino-3-bicyclo[3.3.1]nonanyl)-(4-benzyl-5-methyl-1,4-diazepan-1-yl)methanone dihydrochloride Chemical compound Cl.Cl.CC1CCN(CCN1Cc1ccccc1)C(=O)C1CC2CCCC(C1)C2N DPEYHNFHDIXMNV-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14834377A JPS5480406A (en) | 1977-12-09 | 1977-12-09 | Preparation of urokinase for injection |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14834377A JPS5480406A (en) | 1977-12-09 | 1977-12-09 | Preparation of urokinase for injection |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5480406A JPS5480406A (en) | 1979-06-27 |
JPS629092B2 true JPS629092B2 (fr) | 1987-02-26 |
Family
ID=15450638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP14834377A Granted JPS5480406A (en) | 1977-12-09 | 1977-12-09 | Preparation of urokinase for injection |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5480406A (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4370417A (en) * | 1980-04-03 | 1983-01-25 | Abbott Laboratories | Recombinant deoxyribonucleic acid which codes for plasminogen activator |
US6372716B1 (en) * | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
JPWO2011149016A1 (ja) * | 2010-05-26 | 2013-07-25 | 公立大学法人奈良県立医科大学 | 血栓溶解酵素含有複合体 |
-
1977
- 1977-12-09 JP JP14834377A patent/JPS5480406A/ja active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS5480406A (en) | 1979-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU202761B (en) | Process for producing stabilized erythropoietin compositions | |
JP3140409B2 (ja) | 安定なプロスタグランジンe1−含有注射剤組成物 | |
JP2012167132A (ja) | N−[o−(p−ピバロイルオキシベンゼンスルホニルアミノ)ベンゾイル]グリシン・モノナトリウム塩・4水和物の凍結乾燥製剤 | |
US4089944A (en) | Rapidly solubilized AHF composition and process for preparing same | |
KR101468153B1 (ko) | 5α-안드로스테인-3β,5,6β-트리올 주사제 및 제조방법 | |
CN106692120A (zh) | 利多卡因的药物组合物及其用途 | |
KR20090095668A (ko) | 포르시토사이드 주사제와 그 제조 방법 | |
EP0124018B1 (fr) | Préparation pharmaceutique contenant de la fibrinonectine purifiée | |
EP0233615B1 (fr) | Préparation aqueuse et son procédé de fabrication | |
JPH0749373B2 (ja) | 有機酸を有効成分とする水性液剤の製造法 | |
JP3720262B2 (ja) | 安定化したカルベジロール注射溶液 | |
US4029767A (en) | Pharmaceutical compositions of stable urokinase-heparin complexes and methods for use thereof | |
JPS629092B2 (fr) | ||
JPH0136445B2 (fr) | ||
JP2002508330A (ja) | ダルホプリスチンおよびキヌプリスチンに基づく医薬組成物ならびに調製 | |
US2791531A (en) | Erythromycin thiocyanate and compositions containing same | |
CN100467024C (zh) | 氯诺昔康注射用组合物及其制备方法 | |
US20060252804A1 (en) | Flupirtin injectable galenic form | |
JP2001163776A (ja) | 安定化された液剤 | |
JPH0343251B2 (fr) | ||
CA1066189A (fr) | Preparation d'un produit contenant le facteur antihemophilique, qui passe rapidement en solution | |
JP3088744B2 (ja) | フィブロネクチン組成物 | |
CA1062157A (fr) | Solutions stables pretes a l'injection | |
CN113577020B (zh) | 一种玻璃体腔内注射剂、其制备方法及应用 | |
JP3242924B2 (ja) | 調製済みのアゾセミド(azosemide)注射液 |